Why GRAIL (GRAL) Is Up 12.9% After Positive FDA Panel Verdict On Galleri Trial Results
GRAIL (GRAL) stock rose 12.9% following a positive FDA advisory committee vote on its Galleri multi-cancer early detection blood test, supported by strong results from the PATHFINDER 2 study. The test demonstrated high accuracy in detecting multiple cancers and identifying their origin, with a low false-positive rate. This regulatory progress is expected to reinforce GRAIL's investment narrative, although potential risks include high cash burn and the timing of broad reimbursement.
GRAL Stock Extends Run As Bulls Press Momentum
GRAIL Inc. (GRAL) stock has surged by 8.29%, continuing a rapid run from the mid-$70s to the mid-$140s in weeks, driven by strong momentum and aggressive buying despite significant financial losses. While the company exhibits a rich valuation and negative margins, its strong cash position and low debt offer operational runway, making it a purely sentiment-driven trading vehicle. Active traders are focusing on GRAL's price action and technical patterns, highlighting the importance of disciplined risk management given its fundamental weaknesses.
UBS Adjusts GRAIL Price Target to $175 From $105, Maintains Buy Rating
UBS has significantly increased its price target for GRAIL, Inc. (GRAL) to $175 from the previous $105, while reaffirming its "Buy" rating. This adjustment follows recent positive developments, including an FDA panel's vote to support GRAIL's cancer detection test, Galleri, moving it closer to potential FDA approval. The news has already led to a notable increase in GRAIL's stock performance.
Grail’s cancer blood test nears landmark FDA approval, but insurance coverage looms
Grail's Galleri blood test is close to FDA approval, which would be a significant step towards wider adoption. However, securing health insurance coverage from both private insurers and government programs like Medicare is the next major hurdle for the multi-cancer early detection test. Widespread coverage could lead to a multi-billion dollar market, but concerns remain regarding follow-up costs, uncertain benefits, and the need for further research to confirm its impact on reducing cancer deaths.
GRAIL Slides 4.7% as Post-Rally Profit Taking Appears to Offset Recent Bullish Catalysts
GRAIL (GRAL) shares dropped 4.7% due to potential profit-taking after a late-September rally, despite positive regulatory news for its Galleri test and a raised price target from a Wall Street firm. The decline may also be influenced by recent insider sales and a softer market. Insider trading data shows significant sales by executives, while institutional investors show mixed activity in their holdings.
Securities Class Action Lawsuit Filed Against GRAIL, Inc. (GRAL) – Levi & Korsinsky Represents Shareholders
Levi & Korsinsky, LLP has filed a securities class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made misleading statements regarding its NHS-Galleri trial, concealing that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers. Following GRAIL's announcement on February 19, 2026, that the primary endpoint was not met, the company's stock price dramatically declined by approximately 50.55%.
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
Grail (GRAL), known for its Galleri blood test for early cancer detection, is presented as a strong buy. Despite a setback in an NHS England trial, an FDA panel has endorsed premarket approval, and the company already generates significant revenue from cash sales. Its current valuation is considered reasonable given its long-term growth potential, especially if FDA approval broadens its market.
The Holy Grail In Cancer? FDA Panel Backs Blood Tests.
Trading in Grail (GRAL) stock was halted after a Food and Drug Administration panel issued a mixed vote in favor of the company's Galleri blood screening test for cancer. This marks a significant step towards potential FDA approval for the test, which aims to detect various cancers in asymptomatic individuals. Earlier detection of cancer generally leads to easier and more effective treatment.
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
GRAIL, Inc. announced that the FDA's Medical Devices Advisory Committee voted favorably for the approval of its Galleri® multi-cancer early detection test (MCED). The committee supported Galleri's safety unanimously, effectiveness by a vote of six to four, and overall benefit-risk profile by seven to two with one abstention. GRAIL will continue to work with the FDA as it completes its review of the PMA application, which is a significant step towards potentially making the test widely available.
FDA panel endorses first-of-a-kind cancer blood test from Grail
A federal health advisory panel has endorsed Grail Inc.'s Galleri blood test for detecting signs of various cancers in healthy individuals, despite acknowledging uncertainties about its effectiveness and the need for further study. The panel voted 7-2 that the benefits outweigh the risks, paving the way for potential widespread adoption if the FDA agrees, though they stressed it should supplement, not replace, existing cancer screenings.
FDA panel endorses first-of-a-kind cancer blood test from Grail
A federal advisory panel has endorsed Grail Inc.'s Galleri blood test, designed to detect signs of various cancers in apparently healthy individuals. The panel voted 7-2 that the test offers more potential benefits than risks, despite questions about its efficacy. This marks the first time a federal advisory group has backed such an experimental approach, potentially paving the way for wider adoption if the FDA agrees.
FDA advisory panel recommends a first: multi-cancer blood test
An FDA advisory panel has recommended approval for Grail's Galleri blood test, the first multi-cancer detection blood test, for individuals aged 50 and over. While the test can detect up to 50 forms of cancer, concerns were raised about its effectiveness in early detection and potential for false senses of security. The panel's recommendation includes caveats for marketing materials, emphasizing that the test should supplement, not replace, standard cancer screenings.
GRAIL (GRAL) Stock Looks Overvalued On Its 131% One Year Run
GRAIL (GRAL) stock has surged 131% over the past year, driven by enthusiasm for its Galleri multi-cancer early detection test and recent funding. However, the article suggests the stock looks overvalued based on its Price-to-Sales (P/S) ratio of 29.3x, which is more than double the biotech sector average. While positive FDA commentary and new financing have boosted sentiment, the current valuation raises a warning flag regarding whether the share price growth is sustainable given its sales base.
Samsung’s $110 mn Grail bet poised to pay off as FDA review lifts cancer test hopes
Samsung Electronics and Samsung C&T are experiencing significant unrealized gains from their $110 million investment in Grail Inc., following a 34% share increase after a preliminary FDA review. This development boosts hopes for approval of Grail's flagship cancer blood test, Galleri, which could accelerate Samsung's expansion into cancer screening and digital healthcare across Asia. The article highlights Samsung's broader strategy of investing in biotechnology and diagnostics through various US-based firms to target new growth engines.
GRAIL, Inc. stock surges 33% to $107.97, but RSI hits 81 ahead of FDA call
GRAIL, Inc. stock surged 33.68% to $107.97 on September 21, driven by optimism for FDA approval of its Galleri cancer test ahead of the September 23 Advisory Committee meeting. Despite the bullish sentiment and strong technical indicators, the stock is deeply overbought with an RSI above 80 on daily and hourly charts, and trading outside its daily Bollinger Bands, suggesting a high risk of mean-reversion or a pullback. Short-term momentum is already showing signs of cooling off, according to the 15-minute chart.
Up to $5.8M in insider stock may be sold at GRAIL, Inc. (GRAL)
GRAIL, Inc. (GRAL) insider Joshua Ofman has filed a Rule 144 notice indicating the potential sale of up to 71,452 shares of common stock through Morgan Stanley Smith Barney, valued at approximately $5.77 million. These shares originate from exercised stock options and Restricted Stock Units. The filing also notes previous 10b5-1 sales by Ofman totaling 5,000 shares for $425,098.00 in August 2026.
GRAIL Stock Jumped 34% Yesterday. The FDA Just Told Its Investors Why.
GRAIL stock surged 34% after FDA staff found no major safety or accuracy issues with its Galleri cancer test, ahead of an advisory committee vote. Despite the jump, the average analyst price target of $79 is significantly below the current $108 share price, indicating the Street has not yet caught up to the market's positive reaction. The FDA's remaining questions primarily concern labeling, not the test's core validity or safety, easing investor concerns about approval.
(GRAL) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-driven analysis of Grail Inc Com (NASDAQ: GRAL), indicating mixed sentiment and choppy conditions. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal data highlighting support and resistance levels.
Grail CEO Joshua Ofman sells $425,098 in company stock
GRAIL, Inc. CEO Joshua J. Ofman sold 5,000 shares of company stock for $425,098 on August 27, 2026, with shares priced between $85.00 and $85.11. Despite the stock's 142% return over the past year and a recent revenue beat, GRAIL faces volatility and investor concerns due to a loss per share and uncertainty regarding FDA approval. Mr. Ofman now directly holds 397,271 shares after the transaction.
Grail CFO Aaron Freidin sells $671,579 in company stock
GRAIL, Inc. CFO Aaron Freidin sold 7,900 shares of company stock for $671,579 on August 27, 2026, after the stock surged 142% but has since pulled back. This sale leaves him with 253,083 directly owned shares. The company recently reported Q2 revenue of $44.7 million, exceeding expectations, but also a significant loss and ongoing challenges with FDA approval, which led to a stock decline.
GRAIL Inc Revenue Breakdown – LSX:A40F8M
GRAIL Inc (LSX:A40F8M) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top-performing "Screening" segment, an increase from 104.93 million EUR in the previous year. The United States was the largest geographical contributor, accounting for 116.72 million EUR in revenue.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
Faruqi & Faruqi, LLP is investigating potential securities claims against Grail, Inc. (NASDAQ: GRAL) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action lawsuit is August 4, 2026. The lawsuit alleges that Grail made false and misleading statements regarding the success likelihood of its NHS-Galleri trial, leading to a significant stock price drop after the company announced its primary endpoint was not met. Investors who purchased GRAL stock between May 13, 2024, and February 19, 2026, and suffered losses are encouraged to contact the firm.
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Grail, Inc. (NASDAQ: GRAL) who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial, specifically concerning the sufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the firm to discuss their legal rights.
GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to join before the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL and its executives misled investors about the NHS-Galleri cancer screening trial's design and efficacy, particularly concerning the sufficiency of its three-year follow-up period. GRAIL's stock plummeted by 50.55% on February 19, 2026, after the company disclosed that the trial failed to meet its primary endpoint and admitted to a flawed timeline, leading to over $2.2 billion in market cap loss.
$GRAL Securities: Suffer Losses on Your GRAIL, Inc.
Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50% stock drop after the trial failed to meet its primary endpoint. Investors who suffered losses are encouraged to contact BFA Law before the August 4, 2026, lead plaintiff deadline.
GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
GRAIL, Inc., a healthcare company focused on early cancer detection, announced it will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11 at 10:00 a.m. ET. The company aims to alleviate the global burden of cancer by using advanced sequencing and machine learning to detect multiple cancer types in earlier stages. A webcast of the presentation will be available on GRAIL's investor relations website.
GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
GRAIL (Nasdaq: GRAL) announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, at 10:00 a.m. ET. Live and replay webcasts of the presentation will be available through GRAIL's investor relations website, with the replay archived for at least 30 days. This event provides investors with an opportunity to learn more about GRAIL's mission to detect cancer early.
GRAL Deadline: Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm is notifying stockholders of GRAIL, Inc. (NASDAQ: GRAL) about a class action lawsuit for alleged misleading statements made between May 13, 2025, and February 19, 2026. The lawsuit claims GRAIL concealed material adverse facts regarding its NHS-Galleri trial's sufficiency to demonstrate a reduction in Stage III-IV cancers. Shareholders have until August 4, 2026, to file as lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in Grail’s NHS-Galleri trial, thereby harming investors. Investors who purchased Grail securities between May 13, 2025, and February 19, 2026, are encouraged to join the class action, with a lead plaintiff deadline of August 4, 2026.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL
SueWallSt is reminding shareholders of Grail, Inc. (NASDAQ: GRAL) about the lead plaintiff deadline of August 4, 2026, in a securities class action lawsuit. The lawsuit alleges that Grail's management made misleading representations about the NHS-Galleri trial, leading to a significant stock price drop after the trial's primary endpoint was not met. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and suffered losses, may be eligible for compensation and are encouraged to contact SueWallSt for a no-cost case evaluation.
Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld crucial internal data suggesting the NHS-Galleri trial's three-year design was insufficient to achieve its primary endpoint, leading to a significant stock price drop when the trial failed. Investors who suffered losses are encouraged to contact the firm to recover damages.
GRAIL to Announce Second Quarter 2026 Financial Results
GRAIL, Inc. (Nasdaq: GRAL) announced it will release its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. Interested parties can find a link to the live webcast and recorded replay on the investor relations section of GRAIL's website.
Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against GRAIL, Inc. on behalf of investors who purchased common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false and misleading statements regarding the NHS Galleri trial, specifically concerning its sufficiency to demonstrate a reduction in Stage III-IV cancers and the company's refusal to provide detailed trial results. Investors have until August 4, 2026, to apply for lead plaintiff status.
Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for allegedly making false and misleading statements regarding its NHS Galleri trial. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the firm by August 4, 2026, to discuss potentially becoming lead plaintiff. The lawsuit claims GRAIL concealed issues with the trial's ability to demonstrate a reduction in Stage III-IV cancers, leading to a significant stock price drop after negative trial results were revealed on February 19, 2026.
GRAIL webcast on Aug. 5 results open to all interested parties
GRAIL (Nasdaq: GRAL) will announce its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. The live webcast and recorded replay will be accessible via the investor relations section of GRAIL's website, and interested participants are encouraged to register in advance.
Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the pending class action. The lawsuit alleges that Grail's leadership withheld crucial information about the NHS-Galleri trial's insufficient timeline, despite internal data suggesting the trial would fail its primary endpoint. GRAL shares experienced a significant decline of 50.55%, or $51.32 per share, after the trial's failure was disclosed, and investors have until August 4, 2026, to submit lead plaintiff applications.
GRAIL, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 4, 2026
Bernstein Liebhard LLP reminds GRAIL, Inc. (NASDAQ: GRAL) investors that they have until August 4, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made materially false and misleading statements between May 13, 2025, and February 19, 2026, leading to artificially inflated stock prices and investor losses. Investors who purchased shares during this period and suffered losses are encouraged to contact the firm.
GRAL Court Deadline: GRAIL, Inc. Investor Deadline in Securities Fraud Class Action is August 4 – Contact BFA Law if You Lost Money
Bleichmar Fonti & Auld LLP has announced a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which caused a 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint. Investors who lost money are encouraged to contact BFA Law by the lead plaintiff deadline of August 4, 2026.
BlackRock (GRAL holder) discloses 7.9% GRAIL, Inc. stake in 13G/A
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.9% passive ownership stake in GRAIL, Inc. (GRAL). This ownership amounts to 3,376,085 shares of GRAIL common stock, with BlackRock holding sole voting power over 3,312,474 shares and sole dispositive power over all 3,376,085 shares. The filing indicates that no single client of BlackRock exceeds five percent of GRAIL's outstanding common shares.
GRAL 1-WEEK DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL)
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to join before the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL and its executives misled investors about the design and efficacy of its NHS-Galleri cancer screening trial, failing to disclose limitations and resulting in a significant stock price collapse. The firm is investigating when management knew about the trial's flawed timeline.
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated materially false and misleading statements regarding its NHS-Galleri trial, concealing that the trial design was insufficient to demonstrate a reduction in Stage III-IV cancers within the specified follow-up period. Investors have until August 4, 2026, to file a lead plaintiff motion.
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Grail, Inc. on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made false and misleading statements about the NHS-Galleri trial results, concealing that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers. Investors have until August 4, 2026, to file a lead plaintiff motion.
Lost Money on GRAIL, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of GRAIL, Inc. (NASDAQ: GRAL) who purchased shares between May 13, 2025, and February 19, 2026. The firm encourages these shareholders to join a class action lawsuit seeking recovery, stating that the company allegedly provided false and misleading statements regarding its NHS-Galleri trial's potential to reduce Stage III-IV cancers. Following the announcement that the trial's primary endpoint was not met, GRAIL's stock price dramatically declined by over 50% in one day.
Pomerantz LLP Shares Class Action Details With Investors in GRAIL, Inc. – GRAL
Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) following a significant drop in its stock price. The lawsuit stems from Grail's announcement on February 19, 2026, that its NHS-Galleri Trial did not meet its primary endpoint, leading to a more than 50% decline in stock value. Investors who purchased Grail securities during the Class Period have until August 4, 2026, to seek appointment as Lead Plaintiff.
GRAL DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRAL
Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made materially false and misleading statements and/or concealed material adverse facts regarding its NHS-Galleri trial, specifically concerning its sufficiency to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the Rosen Law Firm to join the class action and potentially recover damages.
$GRAL Lawsuit Notice: BFA Law Reminds GRAIL, Inc. Investors
BFA Law has filed a securities fraud class action lawsuit against GRAIL, Inc. following a 50% stock drop. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial by making positive statements about the trial's design and results, despite the three-year timeframe being insufficient to demonstrate the primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case.
AUGUST 4, 2026 GRAL DEADLINE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces a shareholder class action lawsuit against GRAIL, Inc. and its executives for alleged Securities Exchange Act violations. The lawsuit claims that Grail made false and misleading statements regarding its NHS-Galleri trial's primary endpoint, which was not achieved, leading to a significant stock price drop. Investors who suffered substantial losses between
GRAIL, Inc. ($GRAL) Investors Notified of August 4 Court Deadline in Securities Fraud Lawsuit Over Trial Results Allegations
A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ: GRAL) and its executives for securities fraud, stemming from a significant stock drop after the NHS-Galleri cancer trial failed to meet its primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case, which alleges the company made misleading statements about the trial's design and results. The lawsuit claims GRAIL's stock fell over 50% following the announcement that the trial did not show a statistically significant reduction in late-stage cancers.
GRAL 10-DAY DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL)
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to come forward by the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial, failing to disclose limitations which led to a 50.55% stock price collapse on February 19, 2026, after the trial failed to meet its primary endpoint. Hagens Berman is investigating whether management knew earlier about the insufficient follow-up period.
Securities Fraud Class Action Filed Against GRAIL, Inc. (GRAL) - Levi & Korsinsky Reminds Investors of August 4, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made misleading statements regarding its NHS-Galleri trial, ultimately revealing that the primary endpoint of reducing Stage III-IV cancers was not met, leading to a significant stock price drop. Investors who suffered losses are encouraged to contact the firm to explore potential recovery options.
